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S U M M A R Y
Background: We noted only rare reports of cirrhotic patients with bacterial endocarditis (BE). There is
insufﬁcient data on the risk of BE in liver cirrhosis. This is the ﬁrst national population-based study
evaluating the risk of BE in cirrhotic patients.
Methods: We used the National Health Insurance Database, which is derived from the Taiwan National
Health Insurance Program. The study cohort comprised 40 803 patients with cirrhosis and the comparison
cohort consisted of 40 841 randomly selected subjects with a similar age and sex distribution.
Results: Of the total 81 644 patients, 192 (0.24%) experienced BE during the 3-year follow-up period, 121
patients from the study cohort (0.30% of the cirrhotic patients) and 71 patients from the comparison
group (0.17% of non-cirrhotic patients) (p < 0.001). After adjusting for patient age, sex, and comorbid
disorders, the Cox regression analysis showed that cirrhotic patients had a high risk of BE compared to
non-cirrhotic patients during the 3-year follow-up period (hazard ratio 2.04, 95% conﬁdence interval
1.61–2.44, p < 0.001).
Conclusion: We conclude that liver cirrhosis is a risk factor for the occurrence of BE.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Because of the immune-compromised status, cirrhotic patients
are prone to infectious diseases. The most well-studied infectious
diseases in cirrhotic patients are spontaneous bacterial peritonitis,
pneumonia, and urinary tract infection.1,2 Reports of bacterial
endocarditis (BE) in cirrhotic patients are rare.3–7 In one study,
cirrhosis was observed in about 10% of the patients with BE.3
However, it is still not known if cirrhosis is associated with the
occurrence of BE. In order to identify any relationships, we used a
nationwide population-based database to examine the occurrence
of BE among cirrhotic patients during a 3-year follow-up period
and compared this to the general hospitalized population during
the same period.
2. Patients and methods
2.1. Database
We used the Taiwan National Health Insurance Research
Database for this study. Approval for the analysis of this database* Corresponding author. Tel.: +886 5 2648000; fax: +886 5 2648999.
E-mail address: antibody_1@msn.com (C.-C. Tsai).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.12.009in the present study was obtained from the National Health Research
Institute with application and agreement number 100101. The
Taiwan National Health Insurance Bureau and the National Health
Research Institute established and maintain this database. This
database was used to identify all discharges in Taiwan. The National
Health Insurance Program in Taiwan was established in 1995 for all
citizens who live in Taiwan. The National Health Insurance Program
covered more than 98% of Taiwan’s population in 2004. All
researchers were evaluated by the National Health Research
Institute prior to using the National Health Insurance Research
Database and were required to sign a permit to protect the privacy of
patients, the hospital, and health care providers.
2.2. Study sample
The study was designed as a retrospective study. Patients
discharged with a diagnosis of cirrhosis (International Classiﬁca-
tion of Diseases 9th Revision Clinical Modiﬁcation (ICD-9-CM) code
571.5 or 571.2) from January 1, 2004 to December 31, 2004 were
identiﬁed from the database. We excluded patients who were aged
<30 years in order to rule out congenital anomaly-related
cirrhosis. In this cohort study, a total of 40 803 cirrhotic patients
without baseline BE were enrolled. The comparison group
comprised other hospitalized patients without cirrhosis in theses. Published by Elsevier Ltd. All rights reserved.
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similar sex and age distribution. The diagnosis of BE was based on
the modiﬁed Duke criteria in our country. Each patient (n = 81 644)
was individually followed for a 3-year period starting from their
enrolled hospitalization until BE (ICD-9-CM codes 421).8,9
BE-associated factors were selected as comorbid disorders,
including alcoholism (ICD-9-CM codes 291, 303, 305.00–305.03,
571.0–571.3), drug abuse (ICD-9-CM code 304), diabetes mellitus
(DM) (ICD-9-CM code 250.00), chronic renal failure (CRF) (ICD-9-
CM code 585), and congenital or acquired cardiac defects. As in a
previous study, congenital and acquired cardiac defects included
congenital heart disease (ICD-9-CM code 745.xx–747.xx), chronic
rheumatic heart disease (ICD-9-CM code 393.xx–398.xx), cardiac
device (ICD-9-CM code V45.0x), heart replaced (ICD-9-CM code
V42.1, V43.2), and heart valve replaced (ICD-9-CM code V42.2,
V43.3).10 Comorbid disorders were identiﬁed at the enrolled
hospitalization.
2.3. Statistical analyses
The SPSS statistical package (SPSS System for Windows, version
13.0) was used to perform the analyses in this study. Cox
proportional hazard regressions were performed to evaluate the
association between BE and cirrhosis. Finally, we present hazard
ratios (HR) along with the 95% conﬁdence intervals (CI) using a
signiﬁcance level of 0.05 for this study.
3. Results
Table 1 presents the distribution of demographic characteristics
and selected comorbid disorders at baseline for the sampledTable 1
Demographic characteristics and comorbid medical disorders for cirrhotic patients and
Characteristics Liver cirrhosis, n = 40 852 
Total n % 
Gender 
Male 29 013 71.1 
Female 11 790 28.9 
Age, years 
30–44 7071 17.3 
45–59 13 066 32.0 
60–74 14 159 34.7 
>75 6507 15.9 
Drug abuse 10 0.0 
Heart diseasea 206 0.5 
Diabetes 8031 19.7 
CRF 1242 3.0 
Alcoholism 7960 19.5 
CRF, chronic renal failure.
a Heart disease: congenital heart disease, chronic rheumatic heart disease, cardiac d
Table 2
Unadjusted and adjusted hazard ratios for bacterial endocarditis during the 3-year foll
Variables Unadjusted analysis 
HR (95% CI) p-V
Age 1.00 (0.99–1.00) 0
Male 1.13 (0.82–1.56) 0
Drug abuse 21.92 (5.44–88.27) <0
Heart diseasea 6.18 (3.17–12.08) <0
Diabetes 1.67 (1.22–2.29) 0
CRF 3.02 (1.75–5.20) <0
Alcoholism 1.50 (1.01–2.24) 0
Cirrhosis 2.07 (1.54–2.77) <0
HR, hazard ratio; CI, conﬁdence interval; CRF, chronic renal failure.
a Heart disease: congenital heart disease, chronic rheumatic heart disease, cardiac dpatients according to the presence or absence of cirrhosis. Of the
40 803 sampled patients, the mean age was 59.3 years (standard
deviation 13.9 years). In the total 81 644 patients, 192 (0.24%)
experienced BE during the 3-year follow-up period, 121 from the
study cohort (0.30% of the cirrhotic patients) and 71 from the
comparison group (0.17% of the non-cirrhotic patients) (p < 0.001).
Table 2 presents the results of the Cox regression analysis with
the forward stepwise selection procedure based on the likelihood
ratio. After adjustment for patient gender, age, and underlying
comorbid disorders, the hazard of BE in a 3-year period was 2.04
(95% CI 1.61–2.44, p < 0.001) times greater for cirrhotic patients
than for non-cirrhotic patients. Furthermore, the patients with
congenital or acquired cardiac defects (HR 7.22, 95% CI 3.69–14.13,
p < 0.001), DM (HR 1.59, 95% CI 1.16–2.19, p < 0.001), drug abuse
(HR 27.77, 95% CI 6.88–112.15, p < 0.001), and CRF (HR 2.86, 95% CI
1.66–4.95, p < 0.001) had a greater likelihood of BE after
adjustment by other factors.
4. Discussion
Cirrhotic patients, particularly those with advanced disease,
have leukocyte dysfunction and phagocytic defects that make
them prone to focal and systemic bacterial infections. In the study
of Ferna´ndez Guerrero et al., cirrhosis was observed in almost 10%
of BE, and 45% of BE in cirrhotic patients was hospital-acquired,
which was signiﬁcantly higher than that found in the endocarditis
patients who did not have cirrhosis.3 A poor prognosis is noted in
cirrhotic patients with bacterial endocarditis, but whether cirrho-
sis is a risk factor for BE is still unknown due to limited case
numbers and the lack of an appropriate control group. In the study
of Snyder et al., the frequency of BE at autopsy was higher in reference group (n = 81 736)
Reference group, n = 40 884 p-Value
Total n %
0.982
29 043 71.1
11 798 28.9
0.596
7092 17.4
13 096 32.1
14 157 34.7
6496 15.9
28 0.1 0.004
417 1.0 <0.001
7179 17.6 <0.001
1147 2.8 0.046
683 1.7 <0.001
evice, heart replaced, or heart valve replaced.
ow-up period following ﬁrst hospitalization
Adjusted analysis
alue HR (95% CI) p-Value
.593 - -
.445 - -
.001 27.77(6.88–112.15) <0.001
.001 7.22 (3.69–14.13) <0.001
.002 1.59 (1.16–2.19) 0.004
.001 2.86 (1.66–4.95) <0.001
.047 1.20 (0.79–1.82) 0.397
.001 2.04 (1.61–2.44) <0.001
evice, heart replaced, or heart valve replaced.
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However, there was no statistically signiﬁcant difference in the
frequency of BE at autopsy in cirrhotic patients and non-cirrhotic
patients in the study by Denton et al.6 The case number of cirrhotic
patients with BE in previous studies has been very small, so the real
association between cirrhosis and BE remains to be identiﬁed.
Using the National Health Insurance Research Database, our
study aimed to discover whether cirrhosis is a predisposing factor
for BE. BE-related comorbid disorders we chose included DM,
alcoholism, drug abuse, congenital or acquired cardiac defects, and
CRF. These are established factors of BE or are potentially
associated.11–20 Our study also showed congenital or acquired
cardiac defects, drug abuse, DM, and CRF to be independent factors
for BE, compatible with previous studies.11–16 As noted in previous
studies, BE is related to intravenous (IV) drug abuse.12–14 In the
database we selected, we could not identify the real IV drug users
by ICD-9 code. Hence, we could only choose the patients with
substance abuse as confounders by ICD-9 coding. We believe that
for the patients involved in substance abuse there is a high
possibility of IV drug use behavior.
In the present study, the patients with cirrhosis showed an
increased risk of BE, with the adjusted HR during a 3-year follow-
up period being 2.04 (95% CI 1.61–2.44, p < 0.001) compared to the
comparison group. Furthermore, the very large sample size
provided the statistical power to detect a difference in the risk
of BE between the cirrhotic patients and non-cirrhotic patients.
Because of the high risk of the occurrence of BE in cirrhotic
patients, clinical doctors should pay attention to BE in cirrhotic
patients, especially in those who have congenital or acquired
cardiac defects, IV drug abuse, DM, and CRF. To our knowledge, our
study is the ﬁrst reported population-based cohort study
investigating BE in cirrhotic patients.
There are several limitations to the present study. First, we
could not level the risk of BE in all patients according to cardiac
procedures, intravenous procedures, dental procedures, surgical
procedures, cardiac condition, and use of prophylactic anti-
biotics because our database could not provide detailed data for
this. However, we enrolled all BE-associated heart diseases,
including congenital heart disease, chronic rheumatic heart
disease, cardiac device, heart replaced, and heart valve replaced
as a comorbid disorder. Secondly, the exact etiology of liver
cirrhosis was not identiﬁed in this national population-based
study. In our study, the etiology of cirrhosis could only be
classiﬁed into alcohol-related and non-alcohol related. However,
the etiology of cirrhosis in Taiwan has already been well
established in many previous studies, and is mostly related to
hepatitis B virus.21,22 In our study, about 80% of cirrhotic
patients had disease that was non-alcohol related, compatible
with the data in Taiwan. Despite these limitations, our study is
the ﬁrst complete nationwide population-based study to
identify the risk of BE in cirrhotic patients.
In summary, our analysis demonstrates that patients with
cirrhosis are at risk of BE. Clinical doctors should pay attention to
BE in cirrhotic patients, especially in those who have congenital or
acquired cardiac defects, IV drug abuse, DM, and CRF. Further
studies are needed in this area, and also to evaluate the
relationship between the severity of cirrhosis and BE.Acknowledgements
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